Chamberlain C, et al. - An inquiry was set up with regard to the safety and clinical activity of dapirolizumab pegol, a polyethylene glycol conjugated anti-CD40L Fab' fragment, in patients with systemic lupus erythematosus (SLE). The results revealed that dapirolizumab pegol could serve as an effective biological treatment for SLE. In order to address its efficacy and safety, advanced research was warranted.